CVI Holdings’s Neurogene NGNE Stock Holding History

CVI Holdings’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-126,725	Closed	-$2.46M	–	172
2023 Q4	$2.46M	Buy	126,725 +120,496	+1,934%	+$1.73M	5.08%	5
2023 Q3	$98.4K	Buy	+6,229	New	+$92K	0.19%	42

Other funds holding NGNE

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CVI Holdings's NGNE Position: Q1 2024 in Review

CVI Holdings sold out of Neurogene (NGNE) in Q1 2024, closing a stake of 126,725 shares — an estimated $2.46M sold.

CVI Holdings first reported a position in NGNE in Q3 2023 and held it in 2 quarters. The position peaked at $2.46M in Q4 2023. 60 funds tracked by Wall St. Rank hold NGNE as of Q1 2024.

CVI Holdings reported no remaining Neurogene position as of Q1 2024 after selling out during the quarter.
CVI Holdings sold 126,725 Neurogene shares in Q1 2024, an estimated $2.46M.
CVI Holdings first reported a position in Neurogene in Q3 2023 and held it in 2 quarters.
CVI Holdings's Neurogene position peaked at $2.46M in Q4 2023.
60 funds tracked by Wall St. Rank held Neurogene as of Q1 2024.

Based on CVI Holdings's 13F filing for Q1 2024, filed 7 May 2024.